Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Loss M et al. | Influence of long-term cyclosporine or FK 506 therapy on glucose and lipid metabolism in stable liver graft recipients. | 1995 | Transplant. Proc. | pmid:7533365 |
Senninger N et al. | Glucose metabolism following liver transplantation and immunosuppression with cyclosporine A or FK 506. | 1995 | Transplant. Proc. | pmid:7533364 |
Mor E et al. | Weight gain and lipid profile changes in liver transplant recipients: long-term results of the American FK506 Multicenter Study. | 1995 | Transplant. Proc. | pmid:7533363 |
Söderdahl G et al. | FK 506 improves recovery of bile secretion following orthotopic liver transplantation in man. | 1995 | Transplant. Proc. | pmid:7533362 |
Bäckman L et al. | Whole-blood and plasma levels of FK 506 after liver transplantation: results from the US Multicenter Trial. FK506 Multicenter Study Group. | 1995 | Transplant. Proc. | pmid:7533361 |
Abouljoud MS et al. | Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter Trial. US Multicenter Study Group. | 1995 | Transplant. Proc. | pmid:7533360 |
Mueller AR et al. | The superior immunosuppressant according to diagnosis: FK 506 or cyclosporine A. | 1995 | Transplant. Proc. | pmid:7533359 |
Porayko MK et al. | Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from US Multicenter trial. U.S. Multicenter Liver Study Group. | 1995 | Transplant. Proc. | pmid:7533358 |
Platz KP et al. | OKT3 vs FK 506 rescue management of acute steroid-resistant and chronic rejection. | 1995 | Transplant. Proc. | pmid:7533357 |
Yasuhara M et al. | Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. | 1995 | Transplant. Proc. | pmid:7533356 |
Schwartz M et al. | FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization. | 1995 | Transplant. Proc. | pmid:7533355 |
Rucay P et al. | FK 506 as treatment of late acute rejection in liver transplant patients. | 1995 | Transplant. Proc. | pmid:7533354 |
Jain AB et al. | One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events. | 1995 | Transplant. Proc. | pmid:7533353 |
McDiarmid SV et al. | FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial. | 1995 | Transplantation | pmid:7533345 |
Cox KL et al. | An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. | 1995 | Transplantation | pmid:7533344 |
Shapiro R et al. | A prospective randomized trial of FK506-based immunosuppression after renal transplantation. | 1995 | Transplantation | pmid:7533343 |
Cameron AM et al. | Immunophilin FK506 binding protein associated with inositol 1,4,5-trisphosphate receptor modulates calcium flux. | 1995 | Proc. Natl. Acad. Sci. U.S.A. | pmid:7533300 |
Fruman DA et al. | FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells. | 1995 | Eur. J. Immunol. | pmid:7533090 |
Ning YM and Sanchez ER | Stabilization in vitro of the untransformed glucocorticoid receptor complex of S49 lymphocytes by the immunophilin ligand FK506. | 1995 | J. Steroid Biochem. Mol. Biol. | pmid:7532989 |
Morikawa K et al. | Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. | 1994 | Antimicrob. Agents Chemother. | pmid:7532933 |
Van Thiel DH et al. | Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. | 1995 | Am. J. Gastroenterol. | pmid:7532912 |
Cao W et al. | Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. | 1995 | Transplantation | pmid:7532879 |
Surdacka E et al. | [New immunosuppressive drugs in transplantation]. | 1994 | Prz. Lek. | pmid:7532870 |
Dawson VL et al. | Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures. | 1994 | Neuropharmacology | pmid:7532825 |
Wang CR et al. | T cell receptor-mediated signaling events in CD4+CD8+ thymocytes undergoing thymic selection: requirement of calcineurin activation for thymic positive selection but not negative selection. | 1995 | J. Exp. Med. | pmid:7532685 |
Venkataraman L et al. | FK506 inhibits antigen receptor-mediated induction of c-rel in B and T lymphoid cells. | 1995 | J. Exp. Med. | pmid:7532676 |
Kawai M et al. | Pyrrolidine dithiocarbamate inhibits intercellular adhesion molecule-1 biosynthesis induced by cytokines in human fibroblasts. | 1995 | J. Immunol. | pmid:7532665 |
Donnelly JG and Soldin SJ | Partial characterization of a 52 kDa CsA/FK506/rapamycin binding protein. | 1994 | Clin. Biochem. | pmid:7532557 |
Murthy JN et al. | Identification of a 14 kDa FK-506/rapamycin binding immunophilin from calf thymus. | 1994 | Clin. Biochem. | pmid:7532556 |
Shapiro R et al. | A prospective, randomized trial of FK-506 in renal transplantation--a comparison between double- and triple-drug therapy. | 1994 | Clin Transplant | pmid:7532475 |
Konishi M et al. | Effects of FK506 on surface antigen expression by regenerating thymocytes after sublethal irradiation in the rat. | 1994 | Thymus | pmid:7532330 |
Wolter K et al. | Interaction between FK 506 and clarithromycin in a renal transplant patient. | 1994 | Eur. J. Clin. Pharmacol. | pmid:7532134 |
Marx SO et al. | Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. | 1995 | Circ. Res. | pmid:7532117 |
Ryffel B et al. | Nephrotoxicity of immunosuppressants in rats: comparison of macrolides with cyclosporin. | 1994 Nov-Dec | Exp. Nephrol. | pmid:7532090 |
McCauley J | The nephrotoxicity of FK506 as compared with cyclosporine. | 1993 | Curr. Opin. Nephrol. Hypertens. | pmid:7532089 |
Cacciarelli TV et al. | Influence of the timing of FK 506 (Tacrolimus) administration on recovery of renal function from warm ischemic injury in rats. | 1994 Oct-Dec | ASAIO J. | pmid:7532042 |
Richter A et al. | Growth inhibitory effects of FK506 and cyclosporin A independent of inhibition of calcineurin. | 1995 | Biochem. Pharmacol. | pmid:7531976 |
Foster CA et al. | Pharmacological modulation of endothelial cell-associated adhesion molecule expression: implications for future treatment of dermatological diseases. | 1994 | J. Dermatol. | pmid:7531725 |
Timerman AP et al. | Characterization of an exchange reaction between soluble FKBP-12 and the FKBP.ryanodine receptor complex. Modulation by FKBP mutants deficient in peptidyl-prolyl isomerase activity. | 1995 | J. Biol. Chem. | pmid:7531689 |
Lemster BH et al. | IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy. | 1995 | Clin. Exp. Immunol. | pmid:7531627 |
Sekigawa I et al. | FK506 can inhibit apoptotic cell death induced by the HIV-1 envelope glycoprotein gp120. | 1994 | AIDS | pmid:7531458 |
Fukuzaki T et al. | A protocol with FK 506 for inducing unresponsiveness to murine islet allografts. | 1995 | Surgery | pmid:7531371 |
Bennett WM et al. | Nephrotoxicity of immunosuppressive drugs. | 1994 | Miner Electrolyte Metab | pmid:7531274 |
Chen TS et al. | Microbial transformation of immunosuppressive compounds. IV. Hydroxylation and hemiketal formation of ascomycin (immunomycin) by Streptomyces sp. MA 6970 (ATCC No. 55281). | 1994 | J. Antibiot. | pmid:7531195 |
Whiting PH | Acute and chronic nephrotoxicity associated with immunosuppressive drugs. | 1994 | Curr. Opin. Nephrol. Hypertens. | pmid:7531104 |
Borel JF and Baumann G | Molecular mechanisms of immunosuppressive agents. | 1994 | Bull. Mem. Acad. R. Med. Belg. | pmid:7531051 |
Todo S et al. | Abdominal multivisceral transplantation. | 1995 | Transplantation | pmid:7530873 |
Gruessner RW et al. | A prospective study of FK506 versus CsA and pig ATG in a porcine model of small bowel transplantation. | 1995 | Transplantation | pmid:7530871 |
Heeckt PF et al. | Functional impairment of enteric smooth muscle and nerves caused by chronic intestinal allograft rejection regresses after FK506 rescue. | 1995 | Transplantation | pmid:7530870 |
Neuhaus P et al. | Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience. | 1995 | Transplantation | pmid:7530868 |
Fruman DA et al. | The complex of FK506-binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells. | 1995 | J. Immunol. | pmid:7530743 |
Leach KL et al. | A soluble binding assay for measuring 3H-FK506 binding to the hsp56 immunophilin. | 1994 | J Immunoassay | pmid:7530727 |
Tsuchida M et al. | Effects of irradiation, glucocorticoid and FK506 on cell-surface antigen expression by rat thymocytes: a three-colour flow cytofluorometric analysis. | 1994 | Immunology | pmid:7530693 |
Karanam BV et al. | FK 506 metabolism in human liver microsomes: investigation of the involvement of cytochrome P450 isozymes other than CYP3A4. | 1994 Sep-Oct | Drug Metab. Dispos. | pmid:7530623 |
Dawson TM et al. | The immunophilins, FK506 binding protein and cyclophilin, are discretely localized in the brain: relationship to calcineurin. | 1994 | Neuroscience | pmid:7530348 |
Petros AM and Fesik SW | Nuclear magnetic resonance methods for studying protein-ligand complexes. | 1994 | Meth. Enzymol. | pmid:7530321 |
Eng WK et al. | The yeast FKS1 gene encodes a novel membrane protein, mutations in which confer FK506 and cyclosporin A hypersensitivity and calcineurin-dependent growth. | 1994 | Gene | pmid:7530227 |
Wera S et al. | Rapamycin, FK506 and cyclosporin A inhibit human prolactin gene expression. | 1995 | FEBS Lett. | pmid:7530217 |
Zarnt T et al. | Time-dependent inhibition of peptidylprolyl cis-trans-isomerases by FK506 is probably due to cis-trans isomerization of the inhibitor's imide bond. | 1995 | Biochem. J. | pmid:7529995 |
Shipston MJ et al. | Glucocorticoid negative feedback in pituitary corticotropes. Pivotal role for calcineurin inhibition of adenylyl cyclase. | 1994 | Ann. N. Y. Acad. Sci. | pmid:7529975 |
Peattie DA et al. | Three distinct messenger RNAs can encode the human immunosuppressant-binding protein FKBP12. | 1994 | Gene | pmid:7529739 |
Braun W et al. | Three-dimensional structure and actions of immunosuppressants and their immunophilins. | 1995 | FASEB J. | pmid:7529736 |
Atcherson MM and Trifillis AL | Cytotoxic effects of FK506 on human renal proximal tubule cells in culture. | 1994 | In Vitro Cell. Dev. Biol. Anim. | pmid:7529625 |
Clardy J | The chemistry of signal transduction. | 1995 | Proc. Natl. Acad. Sci. U.S.A. | pmid:7529414 |
Alamartine E et al. | In-vitro effects of cyclosporin A, FK506, 6-mercaptopurine, and prednisolone on lymphokine-activated killer cells. | 1994 | Nephrol. Dial. Transplant. | pmid:7529381 |
Morozumi K and Takeda A | [Kidney disorders induced by immunosuppressive agents]. | 1994 | Nippon Naika Gakkai Zasshi | pmid:7529294 |
Burkhalter EL et al. | Severe neurological complications following orthotopic liver transplantation in patients receiving FK 506 and prednisone. | 1994 | J. Hepatol. | pmid:7529272 |
Cardenas ME et al. | Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands. | 1994 | EMBO J. | pmid:7529175 |
Kraus-Friedmann N and Feng L | Reduction of ryanodine binding and cytosolic Ca2+ levels in liver by the immunosuppressant FK506. | 1994 | Biochem. Pharmacol. | pmid:7529023 |
Coghlan VM et al. | Association of protein kinase A and protein phosphatase 2B with a common anchoring protein. | 1995 | Science | pmid:7528941 |
Douglas CM et al. | The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase. | 1994 | Proc. Natl. Acad. Sci. U.S.A. | pmid:7528927 |
Sandborn WJ et al. | Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue. | 1995 | Hepatology | pmid:7528712 |
Chaudhuri B et al. | The interaction between the catalytic A subunit of calcineurin and its autoinhibitory domain, in the yeast two-hybrid system, is disrupted by cyclosporin A and FK506. | 1995 | FEBS Lett. | pmid:7528690 |
Klaus GG et al. | Properties of mouse CD40. Ligation of CD40 activates B cells via a Ca(++)-dependent, FK506-sensitive pathway. | 1994 | Eur. J. Immunol. | pmid:7528676 |
Moudgil A et al. | Inhibition of in vitro immunoglobulin production by a novel immunosuppressive drug brequinar sodium. | 1994 | Transplant Sci | pmid:7528627 |
Echigo Y et al. | Effects of cyclosporine and tacrolimus (FK 506) on acute pancreatitis in mice. | 1995 | Arch Surg | pmid:7528496 |
Bennett WM et al. | Nephrotoxicity of immunosuppressive drugs. | 1994 | Nephrol. Dial. Transplant. | pmid:7528363 |
Monfar M et al. | Activation of pp70/85 S6 kinases in interleukin-2-responsive lymphoid cells is mediated by phosphatidylinositol 3-kinase and inhibited by cyclic AMP. | 1995 | Mol. Cell. Biol. | pmid:7528328 |
Sugiyama E et al. | FK506, an immunosuppressant, partially inhibits interleukin 6 production by adherent rheumatoid synovial cells. | 1994 | J. Rheumatol. | pmid:7528280 |
Hachida M et al. | [The rescue effect of FK506 in refractory rejection after cardiac transplantation]. | 1994 | Nihon Kyobu Geka Gakkai Zasshi | pmid:7528255 |
Stan R et al. | Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue. | 1994 | J. Biol. Chem. | pmid:7528205 |
Yli-Kauhaluoma J and Janda KD | Twisted alpha-keto amides as transition-state analogues for acyl-transfer reactions: synthesis of the immunoconjugates. | 1994 | Bioorg. Med. Chem. | pmid:7528089 |
Suzuki S | FK506 and deoxyspergualin: experimental studies and clinical applications. | 1994 | Transpl. Immunol. | pmid:7528087 |
Hossain M et al. | Eosinophil viability-enhancing activity in mite-sensitive bronchial asthma. | 1994 | Intern. Med. | pmid:7528071 |
Yamamoto S and Kato R | Hair growth-stimulating effects of cyclosporin A and FK506, potent immunosuppressants. | 1994 | J. Dermatol. Sci. | pmid:7528050 |
Tanabe M et al. | The influence of donor and recipient strains in isolated small bowel transplantation in rats. | 1994 | Transplant. Proc. | pmid:7527986 |
Mueller AR et al. | Increased rejection after liver transplantation in FK 506-treated patients is associated with viral hepatitis C disease. | 1994 | Transplant. Proc. | pmid:7527984 |
Lemmens HP et al. | Outcome following orthotopic liver transplantation in HBsAg-positive patients using short- or long-term immunoprophylaxis. | 1994 | Transplant. Proc. | pmid:7527983 |
Reggiani P et al. | Conversion to rescue therapy with FK 506: data from eight liver transplant patients. | 1994 | Transplant. Proc. | pmid:7527982 |
Kinoshita I et al. | Immunosuppression with FK 506 insures good success of myoblast transplantation in MDX mice. | 1994 | Transplant. Proc. | pmid:7527978 |
Asselin I et al. | Polymerase chain reaction-based assay to assess the success of myoblast transplantation in mdx mice. | 1994 | Transplant. Proc. | pmid:7527970 |
Tsugita M et al. | Hepatocytes or liver nonparenchymal cells plus FK 506 prolong liver xenograft survival. | 1994 | Transplant. Proc. | pmid:7527969 |
Ricordi C et al. | Donor bone marrow cell infusion without recipient cytoablation induces acceptance of rat islet allografts. | 1994 | Transplant. Proc. | pmid:7527967 |
Ericzon BG | Early graft function in liver transplantation patients. | 1994 | Transplant. Proc. | pmid:7527965 |
Morris R | Modes of action of FK506, cyclosporin A, and rapamycin. | 1994 | Transplant. Proc. | pmid:7527964 |
Frei U and Wagner K | Renal function in liver transplant patients receiving FK506 or cyclosporin A immunosuppressive therapy. | 1994 | Transplant. Proc. | pmid:7527963 |
Sewing KF | Pharmacokinetics, dosing principles, and blood level monitoring of FK506. | 1994 | Transplant. Proc. | pmid:7527962 |
Neuhaus PJ | Optimised first-line FK506-based protocols in liver transplantation: experience from the University Hospital Rudolf Virchow, Berlin. | 1994 | Transplant. Proc. | pmid:7527961 |
Reduced incidence of acute, refractory acute, and chronic rejection after liver transplantation with FK506-based immunosuppression. European FK506 Multicentre Liver Study Group. | 1994 | Transplant. Proc. | pmid:7527960 | |
Candinas D et al. | Efficacy of leflunomide in combination with current immunosuppressive agents in rat cardiac allotransplantation. | 1994 | Transplant. Proc. | pmid:7527959 |